Trial Profile
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nirogacestat (Primary)
- Indications Adenocarcinoma; Breast cancer; Triple negative breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms RHEA
- 06 Aug 2020 This trial has been Discontinued in Belgium according to European Clinical Trials Database record.
- 29 Oct 2015 Status changed from recruiting to withdrawn prior to enrolment as reported ClinicalTrials.gov record.
- 07 Jun 2015 Status changed from not yet recruiting to recruiting as reported ClinicalTrials.gov record.